C. Ng

发表

Population pharmacokinetics of exendin‐(9‐39) and clinical dose selection in patients with congenital hyperinsulinism

S. Seeholzer, Diva D. De León, C. Ng, 2018, British journal of clinical pharmacology.

Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey

Jin Y. Jin, C. Ng, P. Fielder, 2016, The AAPS Journal.

Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.

S. Iyer, C. Ng, P. Fielder, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

A. Tolcher, G. Weiss, G. Wilding, 2008, Clinical Cancer Research.

Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

H. Lowman, A. Joshi, Y. Deniz, 2008, The AAPS Journal.

Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague–Dawley Rats

C. Ng, D. Hardiansyah, 2022, Pharmaceutical Research.

Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans

C. Ng, D. Hardiansyah, 2018, Pharmaceutical Research.

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys

Jin Y. Jin, S. Ramanujan, S. Girish, 2014, Pharmaceutical Research.

Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors

E. Tsakalozou, M. Leggas, S. Arnold, 2019, Investigational New Drugs.

Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T‐Cell Therapy

C. Ng, D. Hardiansyah, 2019, Clinical and translational science.

Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma.

H. Bada, M. Leggas, C. Ng, 2019, Biomedical chromatography : BMC.

Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial

D. Combs, B. Davies, R. Bruno, 2005, Journal of clinical pharmacology.

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

A. Tolcher, C. Geyer, C. Takimoto, 2009, Cancer Chemotherapy and Pharmacology.

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab.

Benjamin Wu, A. Joshi, C. Ng, 2006, Journal of pharmaceutical sciences.

A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer

A. Tolcher, R. Kurzrock, A. Patnaik, 2007 .

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

J. Doroshow, C. Takimoto, J. Grem, 2007, Clinical Cancer Research.

POPULATION PHARMACOKINETICS OF RITUXIMAB IN RA PATIENTS: COMBINING TWO PHASE II STUDIES PAGE 2005

B. Davies, M. Levi, C. Ng, 2005 .

Rational Clinical Dose Selection of Adeno‐Associated Virus‐Mediated Gene Therapy Based on Allometric Principles

H. Wong, C. Ng, Fei Tang, 2021, Clinical pharmacology and therapeutics.

Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments

H. Bada, M. Leggas, C. Ng, 2021, Clinical and translational science.

Quantitative Pharmacology Approach to Select Optimal Dose and Study the Important Factors in Determining Disposition of Therapeutic Monoclonal Antibody in Pediatric Subjects - Some Considerations

C. Ng, D. Hardiansyah, 2019, Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases.

Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis

B. Lum, C. Ng, S. Kelsey, 2006, Pharmaceutical Research.

Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer

J. Talbert, C. Ng, Fei Tang, 2020, PloS one.

A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples

Robert J. Bauer, Serge Guzy, Chee Ng, 2007, The AAPS Journal.

Pharmacokinetics/Pharmacodynamics of Nondepleting Anti-CD4 Monoclonal Antibody (TRX1) in Healthy Human Volunteers

L. Vaickus, C. Ng, P. Fielder, 2006, Pharmaceutical Research.

Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis

A. Joshi, M. Garovoy, C. Ng, 2005, Pharmaceutical Research.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis

J. Barrett, Li-jun Zhu, Y. Ming, 2013, Pharmacogenetics and genomics.

Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2).

B. Lum, Yong-Hae Han, C. Ng, 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts

M. Belvin, N. Lewin-Koh, L. Berry, 2012, Cancer Chemotherapy and Pharmacology.

Minimal physiologically‐based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti‐VEGF humanized IgG1 antibody in cynomolgus monkey

C. Ng, D. Hardiansyah, 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Incorporation of FcRn‐mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients

C. Ng, 2016, Biopharmaceutics & drug disposition.

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients

A. Tolcher, C. Takimoto, C. Ng, 2009, Cancer Chemotherapy and Pharmacology.

Comparison of Neural Network, Bayesian, and Multiple Stepwise Regression‐Based Limited Sampling Models to Estimate Area Under the Curve

C. Ng, 2003, Pharmacotherapy.

The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome

M. Ehrlich, W. Kraft, M. Gastonguay, 2018, Clinical pharmacology and therapeutics.